InfuSystem Holdings, Inc: insider trades · United States · SEC (Form 4)

About InfuSystem Holdings, Inc

InfuSystem Holdings, Inc. is a U.S.-listed healthcare services company traded on NYSE American (within the broader NYSE/NASDAQ universe) in the United States. The company was formed in 2005 and is headquartered in Rochester Hills, Michigan. It operates from seven locations across the United States and Canada, serving hospitals, oncology practices, ambulatory surgery centers, and other alternate-site care providers. For international investors, InfuSystem should be viewed as a niche medical device and services platform that sits at the intersection of outpatient care logistics, reimbursement management, and biomedical equipment support. InfuSystem’s business is organized around two operating platforms. Patient Services is the core clinic-to-home care platform, focused primarily on oncology. The company supplies ambulatory infusion pumps, related disposable supply kits, and the supporting billing, logistics, and payer-management infrastructure needed to deliver complex therapies outside the hospital setting. This is an asset- and relationship-intensive business, built on long-standing ties with oncology practices, a growing network of third-party payers, and capabilities that help move treatments from clinic to home. Device Solutions complements that model by providing rental and sale of new and pre-owned infusion pumps and other durable medical equipment, treatment-related consumables, and biomedical recertification, maintenance, and repair services. From a competitive standpoint, InfuSystem benefits from several practical advantages rather than broad scale. Its pump fleet, service network, and geographic footprint support same-day or next-day delivery in many cases, while its biomedical technicians and repair capabilities help reduce downtime for customers. The company also highlights meaningful barriers to entry, including its contracted payer network, entrenched relationships in outpatient oncology, and the operational complexity of managing pumps across multiple care settings. Although oncology remains the dominant revenue driver, management has been working to diversify into additional therapy areas, including wound care and other outpatient treatment categories. Recent operating updates point to improving momentum. In 2025, InfuSystem reported growth in revenue and profitability, and in early 2026 management said fourth-quarter 2025 revenue increased 7.0% year over year, full-year Adjusted EBITDA rose to $31.5 million, and operating cash flow was strong. The company also emphasized that wound care is becoming a more meaningful growth contributor and noted a restructuring of its largest biomedical services contract, which management described as improving earnings quality and cash generation. In late 2025 and early 2026, InfuSystem reiterated a 2025 revenue growth outlook of 6% to 8% and an Adjusted EBITDA margin at or above 20%, underscoring a business that remains specialized but is increasingly focused on profitable growth. For investors, INFU is a small-cap healthcare service provider with a concentrated oncology base, a modest but growing adjacent-therapy footprint, and exposure to U.S. reimbursement dynamics.